Avanos Medical (AVNS) EBIAT (2016 - 2025)
Avanos Medical (AVNS) has disclosed EBIAT for 13 consecutive years, with -$1.3 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 99.67% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$72.9 million through Dec 2025, up 81.27% year-over-year, with the annual reading at -$72.9 million for FY2025, 81.13% up from the prior year.
- EBIAT hit -$1.3 million in Q4 2025 for Avanos Medical, up from -$1.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $38.7 million in Q4 2022 to a low of -$397.0 million in Q4 2024.
- Historically, EBIAT has averaged -$27.6 million across 5 years, with a median of -$1.3 million in 2025.
- Biggest five-year swings in EBIAT: skyrocketed 1383.33% in 2021 and later crashed 1886.05% in 2025.
- Year by year, EBIAT stood at -$25.7 million in 2021, then surged by 250.58% to $38.7 million in 2022, then crashed by 205.68% to -$40.9 million in 2023, then plummeted by 870.66% to -$397.0 million in 2024, then surged by 99.67% to -$1.3 million in 2025.
- Business Quant data shows EBIAT for AVNS at -$1.3 million in Q4 2025, -$1.4 million in Q3 2025, and -$76.8 million in Q2 2025.